Resources - Action Santé Mondiale

2023 UNHLMs: Declarations alone won’t make “health for all” a reality

Statement

Cooperation for development EU, Cooperation for development FR, HIV/AIDS, TB & Malaria, Promoting transparent and needs-driven EU R&D policies, Promoting transparent and needs-driven French R&D policies

2023 UNHLMs: Declarations alone won’t make “health for all” a reality

Last week, leaders, heads of state and governments from around the world gathered in New York at the occasion of the 78th UNGA. Global Health…

actionsantemondiale25 September 2023

SOTEU 2023 – Global health blackout: a repeat

Statement

Cooperation for development EU, Promoting transparent and needs-driven EU R&D policies

SOTEU 2023 – Global health blackout: a repeat

Global Health Advocates shares its analysis of the SOTEU 2023 and deplores the lack of focus on global health.

actionsantemondiale13 September 2023

Increasing funding for TB R&D in 2023, an emergency

Position paper

Fight against pandemics, HIV/AIDS, TB & Malaria

Increasing funding for TB R&D in 2023, an emergency

Ahead of the UN high-level meeting on TB in September 2023, Global Health Advocates calls on the EU to capitalize on its historic leadership in…

actionsantemondiale7 August 2023

Revision of the MFF: Civil Society’s analysis of the European Commission’s proposal

AnalysisCall to action

Cooperation for development EU, Funding and quality of aid

Revision of the MFF: Civil Society’s analysis of the European Commission’s proposal

CSOs are calling on Member States and the European Parliament to deliver additional resources and flexibility after the release of latest MFF revision by the…

actionsantemondiale24 July 2023

The NDICI – Global Europe Instrument: Is it ambitious enough to deliver for global health?

Policy Note

Cooperation for development EU

The NDICI – Global Europe Instrument: Is it ambitious enough to deliver for global health?

As the EU’s new NDICI - Global Europe starts to bear its fruit, and the European Commission begins to review it, GHA stress how this…

actionsantemondiale26 June 2023

Recommendations

Funding and quality of aid

MAKING IT WORK: What role for MDBs in financing health for all? Our recommendations

At the occasion of the New Global Financing Pact Summit in Paris, Global Health Advocates releases an abridged version with recommendations of its discussion paper…

actionsantemondiale22 June 2023

Can the Paris Summit truly advance global health financing and equity?

Call

Promoting transparent and needs-driven EU R&D policies, Research and Development

Can the Paris Summit truly advance global health financing and equity?

More than one hundred civil society organisations from around the world are calling for concrete results in favour of global health financing and equity at…

actionsantemondiale20 June 2023

If we have strong political will at the upcoming UNHLM on TB in September 2023, I genuinely believe we will be closer to our goal of ending TB by 2030.

Blog series

Promoting transparent and needs-driven EU R&D policies, Research and Development

If we have strong political will at the upcoming UNHLM on TB in September 2023, I genuinely believe we will be closer to our goal of ending TB by 2030.

By Rhea Lobo, an international award-winning filmmaker with a background in health journalism, a Tuberculosis (TB) survivor and a Board Member of the Stop TB…

actionsantemondiale13 June 2023

It’s a crucial moment for us in TB. We have so many opportunities in terms of R&D that shouldn’t be wasted.

Blog series

Promoting transparent and needs-driven EU R&D policies, Research and Development

It’s a crucial moment for us in TB. We have so many opportunities in terms of R&D that shouldn’t be wasted.

By Dr. Lucica Ditiu, a Romanian physician and Executive Director of the Stop TB Partnership.

actionsantemondiale13 June 2023

There really are grounds for optimism, but investment is still too low.

Blog series

Promoting transparent and needs-driven EU R&D policies, Research and Development

There really are grounds for optimism, but investment is still too low.

By Olivier Neyrolles, a researcher at CNRS and the director of IPBS-Toulouse.

actionsantemondiale13 June 2023

Review of the MFF: the case for increased funding for external action

Call to action

Cooperation for development EU, Funding and quality of aid

Review of the MFF: the case for increased funding for external action

CSOs are calling on the European Commission, the European Parliament and the Council to increase resources for external action as part of the multiannual financial…

actionsantemondiale16 May 2023

Funding polio eradication: a cornerstone of pandemic preparedness

Recommendations

Fight against pandemics, HIV/AIDS, TB & Malaria

Funding polio eradication: a cornerstone of pandemic preparedness

At the occasion of the 2023 World Immunization Week, Global Health Advocates release an article about why investing in polio eradication should be a priority.

actionsantemondiale26 April 2023

Discussion Paper – MAKING IT WORK: What role for MDBs in financing health for all?

Report

Funding and quality of aid

Discussion Paper – MAKING IT WORK: What role for MDBs in financing health for all?

At the occasion of the World Bank Group Spring Meetings, Global Health Advocates release a discussion paper on the role of MDBs in financing health…

actionsantemondiale11 April 2023

Joint letter

Promoting transparent and needs-driven EU R&D policies, Research and Development

Joint letter regarding the delayed publication of the EU pharmaceutical legislation revision

Dear President von der Leyen, Today was the scheduled date for the publication of the revised pharmaceutical legislation, an important piece of legislation of the…

actionsantemondiale29 March 2023

TB vaccine R&D: an urgent need for stepping up EU investments

International Day

Fight against pandemics, HIV/AIDS, TB & Malaria

TB vaccine R&D: an urgent need for stepping up EU investments

Today we celebrate World Tuberculosis Day. It is an opportunity to raise awareness about the devastating health, social and economic consequences of tuberculosis (TB) and…

actionsantemondiale24 March 2023

Global Health Advocates’ Statement on the Draft Report of the COVI Committee

Recommendations

Promoting transparent and needs-driven EU R&D policies, Research and Development

Global Health Advocates’ Statement on the Draft Report of the COVI Committee

On 28 February, the Rapporteur of the European Parliament’s COVI Committee, Dolors Montserrat, presented the Committee’s draft report on COVID-19 pandemic: lessons learned and recommendations…

actionsantemondiale14 March 2023

Joint letter

Promoting transparent and needs-driven EU R&D policies, Research and Development

Joint letter requesting the publication of the proposed revision of the EU pharmaceutical legislation

Dear Commissioner Kyriakides, We, the signatory organisations representing civil society, patients, consumers, and healthcare professionals, join other stakeholders in calling the European Commission to publish…

actionsantemondiale9 March 2023

Recommendations

Promoting transparent and needs-driven EU R&D policies, Research and Development

GHA’s recommendations to ensure future EU research programmes really deliver for people

The European Commission recently held the largest public consultation ever on the past, present, and future of the its research programmes: Horizon 2020 and Horizon Europe In…

actionsantemondiale2 March 2023

1 2 3 … 13 Next »

2023 UNHLMs: Declarations alone won’t make “health for all” a reality

SOTEU 2023 – Global health blackout: a repeat

Increasing funding for TB R&D in 2023, an emergency

Revision of the MFF: Civil Society’s analysis of the European Commission’s proposal

The NDICI – Global Europe Instrument: Is it ambitious enough to deliver for global health?

MAKING IT WORK: What role for MDBs in financing health for all? Our recommendations

Can the Paris Summit truly advance global health financing and equity?

If we have strong political will at the upcoming UNHLM on TB in September 2023, I genuinely believe we will be closer to our goal of ending TB by 2030.

It’s a crucial moment for us in TB. We have so many opportunities in terms of R&D that shouldn’t be wasted.

There really are grounds for optimism, but investment is still too low.

Review of the MFF: the case for increased funding for external action

Funding polio eradication: a cornerstone of pandemic preparedness

Discussion Paper – MAKING IT WORK: What role for MDBs in financing health for all?

Joint letter regarding the delayed publication of the EU pharmaceutical legislation revision

TB vaccine R&D: an urgent need for stepping up EU investments

Global Health Advocates’ Statement on the Draft Report of the COVI Committee

Joint letter requesting the publication of the proposed revision of the EU pharmaceutical legislation

GHA’s recommendations to ensure future EU research programmes really deliver for people

Search…

Latest news

Latest news

Adresses

Social Networks

Contact us